ANTIBODY FRAGMENTS SPECIFIC IN RELATION TO HUMAN CANCER-EMBRYONIC ANTIGEN (CEA)

FIELD: biotechnology, in particular tumor immunotherapy. ^ SUBSTANCE: invention relates to monovalent and divalent single-stranded (diantibody) Fv-fragments (scFv) of antibodies obtained by using of extracted RNA producing of hybridoma Mab CB/ior-CEA.1. Antibodies fragments according to the inventio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KREMATA AL'VARES KHOSE AL'BERTO, ASEVEDO KASTRO BORIS EHRNESTO, FREJRE AL'MEIDA FREJJA DE LOS MILAGROS, GAVILONDO KAULI KHORKHE VIKTOR, ROKE NAVARRO LOURDES TAT'JANA, MONTESINO SEKE RAKEL, AJJALA AVILA MARTA, GONSALES LOPES LUIS KHAV'ER, BELL' GARSIA KHANSSEL'
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: biotechnology, in particular tumor immunotherapy. ^ SUBSTANCE: invention relates to monovalent and divalent single-stranded (diantibody) Fv-fragments (scFv) of antibodies obtained by using of extracted RNA producing of hybridoma Mab CB/ior-CEA.1. Antibodies fragments according to the invention have predetermined amino acid sequence (such as defined in sequence list), are specific to human CEA, have CEA affinity constant of (5.0±0.4)x10-9 l/mol for monovalent fragment and (2.8±0.3)x10-10 l/mol for diantibody. Disclosed is application of abovementioned fragments in pharmaceutical compositions for treatment of human CEA-expressing tumors and determination of tumor localization in vivo. Described is modified cell expressing said antibody fragment, as well as multicellular genetically modified organism such as transgenic plant. ScFv fragments of monovalent antibody and diantibody have no Fc-domains and have smaller molecule size than mice Mab and as a result fragments are better penetrate in tissue in vivo and have less immunogenic action in living body. ^ EFFECT: antibody fragments with improved specificity to human cancer-embryonic antigen. ^ 12 cl, 6 dwg, 8 tbl, 9 ex